DOI QR코드

DOI QR Code

Diagnostic value of alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) index combined with γ-glutamyl transferase in differentiating ALD and NAFLD

  • Wang, Junling (Graduate School of Tianjin Medical University, Tianjin Second People's Hospital) ;
  • Li, Ping (Department II of Chinese Integrative Medicine, Tianjin Second People's Hospital, Tianjin Medical University) ;
  • Jiang, Zhilong (Tianjin University of Traditional Chinese Medicine, Tianjin Second People's Hospital) ;
  • Yang, Qiuhui (Graduate School of Tianjin Medical University, Tianjin Second People's Hospital) ;
  • Mi, Yuqiang (Department II of Chinese Integrative Medicine, Tianjin Second People's Hospital, Tianjin Medical University) ;
  • Liu, Yonggang (Department of Pathology, Tianjin Second People's Hospital) ;
  • Shi, Ruifang (Department of Pathology, Tianjin Second People's Hospital) ;
  • Zhou, Yonghe (Department of Radiology, Tianjin Second People's Hospital) ;
  • Wang, Jinsheng (Department of Radiology, Tianjin Second People's Hospital) ;
  • Lu, Wei (Department II of Chinese Integrative Medicine, Tianjin Second People's Hospital, Tianjin Medical University) ;
  • Li, Si (Tianjin University of Traditional Chinese Medicine, Tianjin Second People's Hospital) ;
  • Liu, Dan (Tianjin University of Traditional Chinese Medicine, Tianjin Second People's Hospital)
  • Received : 2015.07.31
  • Accepted : 2015.08.25
  • Published : 2016.05.01

Abstract

Background/Aims: This study aimed to verify the reliability of the alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) index (ANI) for distinguishing ALD in patients with hepatic steatosis from NAFLD, and to investigate whether ANI combined with ${\gamma}$-glutamyl transferase (GGT) would enhance the accuracy of diagnosis in China. Methods: A hundred thirty-nine cases of fatty liver disease (FLD) were divided into two groups of ALD and NAFLD. The ANI was calculated with an online calculator. All indicators and ANI values were analyzed using statistical methods. Results: ANI was significantly higher in patients with ALD than in those with NAFLD ($7.11 {\pm}5.77$ vs. $-3.09 {\pm}3.89$, p < 0.001). With a cut-off value of -0.22, the sensitivity, specificity, and area under the receiver operating characteristic curve (AUROC) of diagnosed ALD cases was 87.1%, 92.5%, and 0.934 (95% confidence interval [CI], 0.879 to 0.969), respectively. The corresponding values for aspartate aminotransferase (AST)/alanine transaminase (ALT), mean corpuscular volume (MCV), and GGT were 75.29%, 72.94%, and 0.826 (95% CI, 0.752 to 0.885); 94.34%, 83.02%, and 0.814 (95% CI, 0.739 to 0.875) and 80.23%, 79.25%, and 0.815 (95% CI, 0.740 to 0.876), respectively. ANI AUROC was significantly higher than the AST/ALT, MCV, or GGT AUROCs (all p < 0.001), moreover, ANI showed better diagnostic performance. The combination of ANI and GGT showed a better AUROC than ANI alone (0.976 vs. 0.934, p = 0.016). The difference in AUROCs between AST/ALT, MCV, and GGT was not statistically significant (all p > 0.05). Conclusions: ANI can help distinguish ALD from NAFLD with high accuracy; when ANI was combined with GGT, its effectiveness improved further.

Keywords

Acknowledgement

Supported by : Tianjin state administration of traditional Chinese medicine

References

  1. Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology 2014;147:754-764. https://doi.org/10.1053/j.gastro.2014.07.056
  2. Day CP. Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int 2006;26:1021-1028. https://doi.org/10.1111/j.1478-3231.2006.01323.x
  3. Toshikuni N, Tsutsumi M, Arisawa T. Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease. World J Gastroenterol 2014;20:8393-8406. https://doi.org/10.3748/wjg.v20.i26.8393
  4. Fan JG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol 2013;28 Suppl 1:11-17.
  5. Frazier TH, Stocker AM, Kershner NA, Marsano LS, Mc-Clain CJ. Treatment of alcoholic liver disease. Therap Adv Gastroenterol 2011;4:63-81. https://doi.org/10.1177/1756283X10378925
  6. Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 2010;16:5286-5296. https://doi.org/10.3748/wjg.v16.i42.5286
  7. Pulzi FB, Cisternas R, Melo MR, Ribeiro CM, Malheiros CA, Salles JE. New clinical score to diagnose nonalcoholic steatohepatitis in obese patients. Diabetol Metab Syndr 2011;3:3. https://doi.org/10.1186/1758-5996-3-3
  8. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:521-533. https://doi.org/10.1016/j.cld.2004.04.004
  9. Mundle G, Ackermann K, Munkes J, Steinle D, Mann K. Influence of age, alcohol consumption and abstinence on the sensitivity of carbohydrate-deficient transferrin, gamma-glutamyltransferase and mean corpuscular volume. Alcohol Alcohol 1999;34:760-766. https://doi.org/10.1093/alcalc/34.5.760
  10. Dunn W, Angulo P, Sanderson S, et al. Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology 2006;131:1057-1063. https://doi.org/10.1053/j.gastro.2006.08.020
  11. Anton RF, Lieber C, Tabakoff B; CDTect Study Group. Carbohydrate-deficient transferrin and gamma-glutamyltransferase for the detection and monitoring of alcohol use: results from a multisite study. Alcohol Clin Exp Res 2002;26:1215-1222.
  12. Litten RZ, Bradley AM, Moss HB. Alcohol biomarkers in applied settings: recent advances and future research opportunities. Alcohol Clin Exp Res 2010;34:955-967. https://doi.org/10.1111/j.1530-0277.2010.01170.x
  13. The Chinese National Workshop on Fatty Liver and Alcoholic Liver Disease for the Chinese Liver Disease Association. Guidelines for management of alcoholic liver disease: an up dated and revised edition. Zhonghua Gan Zang Bing Za Zhi 2010;18:167-170.
  14. The Chinese National Workshop on Fatty Liver and Alcoholic Liver Disease for the Chinese Liver Disease Associ-ation. Guidelines for management of nonalcoholic fatty liver disease: an updated and revised edition. Zhonghua Gan Zang Bing Za Zhi 2010;18:163-166.
  15. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321. https://doi.org/10.1002/hep.20701
  16. Wang XF, Yue M. Relationship between alcohol consumption and clinical manifestation of patients with fatty liver: a single-center study. Hepatobiliary Pancreat Dis Int 2011;10:276-279. https://doi.org/10.1016/S1499-3872(11)60046-5
  17. Macchia T, Mancinelli R, Gentili S, et al. Mitochondrial aspartate aminotransferase isoenzyme: a biochemical marker for the clinical management of alcoholics? Clin Chim Acta 1997;263:79-96. https://doi.org/10.1016/S0009-8981(97)00046-6
  18. Liu YS, Xu GY, Cheng DQ, Li YM. Determination of serum carbohydrate-deficient transferrin in the diagnosis of alcoholic liver disease. Hepatobiliary Pancreat Dis Int 2005;4:265-268.
  19. Kaiser JP, Beier JI, Zhang J, et al. PKCepsilon plays a causal role in acute ethanol-induced steatosis. Arch Biochem Biophys 2009;482:104-111. https://doi.org/10.1016/j.abb.2008.11.004
  20. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011;54:1082-1090.
  21. Yao SK, Gao C. Differential diagnosis between alcoholic liver disease and nonalcoholic fatty liver disease. World Chin J Dig 2010;18:1456-1460. https://doi.org/10.11569/wcjd.v18.i14.1456
  22. Kumar M, Rastogi A, Singh T, et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: does etiology affect performance? J Gastroenterol Hepatol 2013;28:1194-1201. https://doi.org/10.1111/jgh.12134
  23. de Ledinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012;32:911-918. https://doi.org/10.1111/j.1478-3231.2012.02820.x
  24. Becker U, Deis A, Sorensen TI, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996;23:1025-1029. https://doi.org/10.1002/hep.510230513
  25. Mandayam S, Jamal MM, Morgan TR. Epidemiology of alcoholic liver disease. Semin Liver Dis 2004;24:217-232. https://doi.org/10.1055/s-2004-832936
  26. Loomba R, Abraham M, Unalp A, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012;56:943-951. https://doi.org/10.1002/hep.25772
  27. Lomonaco R, Ortiz-Lopez C, Orsak B, et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology 2012;55:1389-1397. https://doi.org/10.1002/hep.25539
  28. Das SK, Mukherjee S, Vasudevan DM, Balakrishnan V. Comparison of haematological parameters in patients with non-alcoholic fatty liver disease and alcoholic liver disease. Singapore Med J 2011;52:175-181.
  29. Cylwik B, Naklicki M, Gruszewska E, Szmitkowski M, Chrostek L. The distribution of serum folate concentration and red blood cell indices in alcoholics. J Nutr Sci Vitaminol (Tokyo) 2013;59:1-8. https://doi.org/10.3177/jnsv.59.1
  30. Fragasso A, Mannarella C, Ciancio A, Sacco A. Functional vitamin B12 deficiency in alcoholics: an intriguing finding in a retrospective study of megaloblastic anemic patients. Eur J Intern Med 2010;21:97-100. https://doi.org/10.1016/j.ejim.2009.11.012
  31. Cohen JA, Kaplan MM. The SGOT/SGPT ratio: an indicator of alcoholic liver disease. Dig Dis Sci 1979;24:835-838. https://doi.org/10.1007/BF01324898
  32. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999;94:1018-1022. https://doi.org/10.1111/j.1572-0241.1999.01006.x
  33. Ono K, Ono T, Matsumata T. The pathogenesis of decreased aspartate aminotransferase and alanine aminotransferase activity in the plasma of hemodialysis patients: the role of vitamin B6 deficiency. Clin Nephrol 1995;43:405-408.
  34. Whitfield JB. Gamma glutamyl transferase. Crit Rev Clin Lab Sci 2001;38:263-355. https://doi.org/10.1080/20014091084227
  35. van Beek JH, de Moor MH, Geels LM, et al. The association of alcohol intake with gamma-glutamyl transferase (GGT) levels: evidence for correlated genetic effects. Drug Alcohol Depend 2014;134:99-105. https://doi.org/10.1016/j.drugalcdep.2013.09.016
  36. Robles-Diaz M, Garcia-Cortes M, Medina-Caliz I, et al. The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity. Liver Int 2015;35:2474-2482. https://doi.org/10.1111/liv.12834

Cited by

  1. A Biomedical Investigation of the Hepatoprotective Effect of Radix salviae miltiorrhizae and Network Pharmacology-Based Prediction of the Active Compounds and Molecular Targets vol.18, pp.3, 2016, https://doi.org/10.3390/ijms18030620
  2. Hepatoprotective Effects of a Functional Formula of Three Chinese Medicinal Herbs: Experimental Evidence and Network Pharmacology-Based Identification of Mechanism of Action and Potential Bioactive Co vol.23, pp.2, 2016, https://doi.org/10.3390/molecules23020352
  3. Prevalence of asymptomatic nonalcoholic fatty liver disease in nondiabetic participants: a study from south india vol.31, pp.None, 2016, https://doi.org/10.4103/ejim.ejim_76_18
  4. Preventive Effect of YGDEY from Tilapia Fish Skin Gelatin Hydrolysates against Alcohol-Induced Damage in HepG2 Cells through ROS-Mediated Signaling Pathways vol.11, pp.2, 2016, https://doi.org/10.3390/nu11020392
  5. Mixed steatohepatitis: more questions than answers (Part 1) vol.92, pp.12, 2016, https://doi.org/10.26442/00403660.2020.12.200470
  6. Fatty liver index and progression to type 2 diabetes: a 5-year longitudinal study in Spanish workers with pre-diabetes vol.11, pp.8, 2016, https://doi.org/10.1136/bmjopen-2020-045498